SCHEMBL3609783

SCHEMBL3609783

CC(=O)NCc1nnc(-c2csc(NC(=N)N)n2)o1

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.40
HSD17B10 Q99714 3/20 0.40
KMT2A Q03164 3/20 0.40
MEN1 O00255 2/20 0.40
ALDH1A1 P00352 2/20 0.40
MAPT P10636 1/20 0.40
AOC3 Q16853 2/20 0.38
ABL1 P00519 5/20 0.37
MAPK1 P28482 2/20 0.37
NPC1 O15118 1/20 0.37
HDAC8 Q9BY41 4/20 0.37
RAB9A P51151 1/20 0.36
LMNA P02545 1/20 0.36
POLB P06746 1/20 0.36
HDAC1 Q13547 1/20 0.36
HDAC2 Q92769 1/20 0.36
ALOX15 P16050 1/20 0.36
PIK3CG P48736 1/20 0.36
TYR P14679 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3607652 0.79 KDM4E (0.44) KDM4EHSD17B10KMT2AMEN1ALDH1A1
SCHEMBL3602005 0.79 KMT2A (0.43) KDM4EHSD17B10KMT2AMEN1ALDH1A1
SCHEMBL3607773 0.77 KMT2A (0.68) KDM4EHSD17B10KMT2AMEN1ALDH1A1
SCHEMBL3608212 0.77 AOC3 (0.39) KDM4EHSD17B10KMT2AMEN1ALDH1A1
SCHEMBL3612358 0.76 AOC3 (0.57) KMT2AMEN1ALDH1A1MAPTAOC3
SCHEMBL3602568 0.75 ABL1 (0.56) KDM4EHSD17B10KMT2AMEN1ALDH1A1
SCHEMBL3606627 0.73 KDM4E (0.45) KDM4EHSD17B10KMT2AMEN1ALDH1A1
SCHEMBL3607745 0.72 ROCK2 (0.56) KDM4EHSD17B10ALDH1A1MAPTABL1
SCHEMBL3601750 0.72 PIK3CG (0.46) KDM4EHSD17B10KMT2AMEN1ALDH1A1
SCHEMBL3607860 0.72 ABL1 (0.55) HSD17B10KMT2AMEN1ALDH1A1AOC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100298340-A1 Thiazol-Guanidine Derivatives Useful As A (Beta)-Related Pathologies ASTRAZENECA AB (SE) 2010-11-25 US claimed
US-20100298340-A1 Thiazol-Guanidine Derivatives Useful As A (Beta)-Related Pathologies ASTRAZENECA AB (SE) 2010-11-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298340-A1 Thiazol-Guanidine Derivatives Useful As A (Beta)-Related Pathologies GRN, MAPT, GUCY1B1 KDM4E 4351/4885HSD17B10 2280/4885KMT2A 4116/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.